antiviral and associated therapy for COVID-19: living meta-analysis of clinical studies

Outcome	Relative effect 95%CI	Trt. better when	I2	k (RCT/OBS)	Bayesian probability	Overall ROB	Publication bias	Degree of certainty	Endpoint importance	Published MA
efficacy endpoints 00
death or ventilation	3.60 [0.13, 102.66]	< 1	0%	1 study (1/-)	23.0 %	NA	not evaluable		important	-
radiologic improvement (14-day)	1.50 [0.08, 28.48]	> 1	87%	2 studies (2/-)	60.4 %	low	not evaluable	high	important	-
safety endpoints 00
adverse events	0.18 [0.04, 0.89]	< 1	38%	2 studies (2/-)	98.2 %	low	not evaluable	high	non important	-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.

antiviral and associated therapy - versus anti-inflammatoty and immuno-therapy - for COVID 19 hospitalized pdf xlsx method abbreviations

efficacy endpoints 00

safety endpoints 00